Renal function must be considered, as some GLP-1 agents require dose adjustment or have limitations in advanced chronic kidney disease
Here's why your medspa should be talking about GLP-1sand what treatments, messaging, and strategies to offer next
For providers expanding into weight loss, this removes the biggest barrier: How do I find patients without gambling thousands on marketing
Pair this with oscillating fans placed low to the ground to help evaporate moisture before it settles into a dangerous puddle
The treatments today are as ineffective as they will ever be, looking ahead: Weight loss efficacy is increasing from 15% to 20% to 25% to 30% The label is expanding from Diabetes to Obesity to Heart Disease and likely Kidney Disease and Sleep Apnea
The Wegovy pill showed around 16.6% weight loss on average in a late-stage trial, while Lilly's oral drug caused roughly 12.4% on average in a separate study, when analyzing patients who stayed on treatment
